$CTSO
Cytosorbents Corp

2020 Q4 Form 10-Q Financial Statement

#000110465920121349 Filed on November 04, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $11.96M $10.55M $6.095M
YoY Change 60.91% 73.04% 6.13%
Cost Of Revenue $2.530M $2.890M $1.696M
YoY Change 21.05% 70.4% -17.36%
Gross Profit $9.428M $7.656M $4.399M
YoY Change 76.71% 74.06% 19.2%
Gross Profit Margin 78.86% 72.59% 72.17%
Selling, General & Admin $9.380M $7.282M $6.108M
YoY Change 30.1% 19.23% 51.15%
% of Gross Profit 99.49% 95.12% 138.86%
Research & Development $2.690M $1.753M $3.185M
YoY Change -24.44% -44.95% 63.89%
% of Gross Profit 28.53% 22.9% 72.41%
Depreciation & Amortization $160.0K $160.0K $130.0K
YoY Change -5.88% 23.08% -7.14%
% of Gross Profit 1.7% 2.09% 2.96%
Operating Expenses $12.06M $9.616M $10.03M
YoY Change 11.98% -4.09% 56.64%
Operating Profit -$2.634M -$1.960M -$5.628M
YoY Change -51.5% -65.18% 107.61%
Interest Expense $830.0K -$260.6K -$302.0K
YoY Change 112.82% -13.69% 63.02%
% of Operating Profit
Other Income/Expense, Net $1.120M -$1.258M
YoY Change -189.06% 327.52%
Pretax Income -$1.800M -$839.7K -$6.885M
YoY Change -64.29% -87.8% 129.14%
Income Tax -$1.130M $0.00 $0.00
% Of Pretax Income
Net Earnings -$680.0K -$839.7K -$6.885M
YoY Change -82.78% -87.8% 129.14%
Net Earnings / Revenue -5.69% -7.96% -112.96%
Basic Earnings Per Share $0.00 -$0.02 -$0.21
Diluted Earnings Per Share $0.00 -$0.02 -$0.21
COMMON SHARES
Basic Shares Outstanding 43.18M 41.59M
Diluted Shares Outstanding 41.59M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $71.40M $88.00M $16.00M
YoY Change 485.25% 450.0% -35.74%
Cash & Equivalents $71.42M $87.98M $15.98M
Short-Term Investments
Other Short-Term Assets $3.200M $1.000M $1.200M
YoY Change 52.38% -16.67% 100.0%
Inventory $2.674M $2.025M $1.800M
Prepaid Expenses
Receivables $5.159M $5.797M $3.400M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $82.45M $96.80M $22.40M
YoY Change 294.48% 332.16% -25.21%
LONG-TERM ASSETS
Property, Plant & Equipment $2.120M $2.078M $3.100M
YoY Change 10.11% -32.98% 84.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.348M $4.270M $3.200M
YoY Change 24.78% 33.43% 22.04%
Total Long-Term Assets $7.497M $7.479M $6.300M
YoY Change 15.68% 18.72% 46.54%
TOTAL ASSETS
Total Short-Term Assets $82.45M $96.80M $22.40M
Total Long-Term Assets $7.497M $7.479M $6.300M
Total Assets $89.95M $104.3M $28.70M
YoY Change 228.5% 263.35% -16.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.835M $2.386M $2.100M
YoY Change -10.01% 13.64% 12.94%
Accrued Expenses $631.6K $5.800M $4.100M
YoY Change 0.39% 41.46% 70.83%
Deferred Revenue $728.4K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $9.167M $3.100M
YoY Change -100.0% 195.7%
Total Short-Term Liabilities $10.15M $17.36M $9.300M
YoY Change 2.18% 86.63% 118.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $5.993M $11.90M
YoY Change -100.0% -49.64% 19.99%
Other Long-Term Liabilities $600.0K $700.0K $800.0K
YoY Change 0.0% -12.5%
Total Long-Term Liabilities $0.00 $5.993M $12.70M
YoY Change -100.0% -52.81% 28.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.15M $17.36M $9.300M
Total Long-Term Liabilities $0.00 $5.993M $12.70M
Total Liabilities $10.73M $24.05M $21.90M
YoY Change -55.2% 9.81% 54.46%
SHAREHOLDERS EQUITY
Retained Earnings -$196.6M -$195.9M
YoY Change 4.15%
Common Stock $43.22K $43.18K
YoY Change 32.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $79.22M $80.23M $6.734M
YoY Change
Total Liabilities & Shareholders Equity $89.95M $104.3M $28.70M
YoY Change 228.5% 263.35% -16.2%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$680.0K -$839.7K -$6.885M
YoY Change -82.78% -87.8% 129.14%
Depreciation, Depletion And Amortization $160.0K $160.0K $130.0K
YoY Change -5.88% 23.08% -7.14%
Cash From Operating Activities -$1.050M -$3.290M -$5.200M
YoY Change -74.58% -36.73% 97.72%
INVESTING ACTIVITIES
Capital Expenditures -$270.0K -$400.0K -$320.0K
YoY Change -32.5% 25.0% 14.29%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$270.0K -$400.0K -$320.0K
YoY Change -32.5% 25.0% 14.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -15.15M 56.38M 5.220M
YoY Change -2042.31% 980.08% 103.11%
NET CHANGE
Cash From Operating Activities -1.050M -3.290M -5.200M
Cash From Investing Activities -270.0K -400.0K -320.0K
Cash From Financing Activities -15.15M 56.38M 5.220M
Net Change In Cash -16.47M 52.69M -300.0K
YoY Change 339.2% -17663.33% -11.76%
FREE CASH FLOW
Cash From Operating Activities -$1.050M -$3.290M -$5.200M
Capital Expenditures -$270.0K -$400.0K -$320.0K
Free Cash Flow -$780.0K -$2.890M -$4.880M
YoY Change -79.09% -40.78% 107.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001175151
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43175685
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32616107
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36792
dei Entity Registrant Name
EntityRegistrantName
CYTOSORBENTS CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0373793
dei Entity Address Address Line1
EntityAddressAddressLine1
7 Deer Park Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite K
dei Entity Address City Or Town
EntityAddressCityOrTown
Monmouth Junction
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08852
dei City Area Code
CityAreaCode
732
dei Local Phone Number
LocalPhoneNumber
329-8885
dei Security12b Title
Security12bTitle
Common Stock $0.001 par value
dei Trading Symbol
TradingSymbol
CTSO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43175685
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87978343
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12232418
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
69640
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
145313
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5797306
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4467087
CY2020Q3 us-gaap Inventory Net
InventoryNet
2024934
CY2019Q4 us-gaap Inventory Net
InventoryNet
2113897
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1002401
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2088127
CY2020Q3 us-gaap Assets Current
AssetsCurrent
96802984
CY2019Q4 us-gaap Assets Current
AssetsCurrent
20901529
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2077542
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1925325
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1131915
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1070762
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4269637
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3484894
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9936267
CY2020Q3 us-gaap Assets
Assets
104282078
CY2019Q4 us-gaap Assets
Assets
27382510
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2386361
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2039222
CY2020Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
9166667
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1666666
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
432423
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
428083
CY2020Q3 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5370857
CY2019Q4 ctso Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5802296
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17356308
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5993125
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
13385522
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
699492
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
642679
CY2020Q3 us-gaap Liabilities
Liabilities
24048925
CY2019Q4 us-gaap Liabilities
Liabilities
23964468
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43175685
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32616107
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
43176
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
32616
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
276656202
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
191648907
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-517302
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
525978
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-195948923
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188789459
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
80233153
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3418042
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104282078
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27382510
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10546612
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6095007
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
29048825
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
17519162
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2890382
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1696274
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8524991
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5269228
CY2020Q3 us-gaap Gross Profit
GrossProfit
7656230
CY2019Q3 us-gaap Gross Profit
GrossProfit
4398733
us-gaap Gross Profit
GrossProfit
20523834
us-gaap Gross Profit
GrossProfit
12249934
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1753455
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3185105
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6124780
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8533342
CY2020Q3 us-gaap Professional Fees
ProfessionalFees
580067
CY2019Q3 us-gaap Professional Fees
ProfessionalFees
733297
us-gaap Professional Fees
ProfessionalFees
1944930
us-gaap Professional Fees
ProfessionalFees
1886851
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7282357
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6107877
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20190193
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15372476
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
9615879
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
10026279
us-gaap Operating Expenses
OperatingExpenses
28259903
us-gaap Operating Expenses
OperatingExpenses
25792669
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1959649
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5627546
us-gaap Operating Income Loss
OperatingIncomeLoss
-7736069
us-gaap Operating Income Loss
OperatingIncomeLoss
-13542735
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-260617
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-301972
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-839972
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-721703
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1380537
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-955543
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1416577
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1051854
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1119920
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1257515
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
576605
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1773557
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-839729
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6885061
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7159464
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-15316292
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-839729
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6885061
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7159464
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15316292
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41593218
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32365700
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37350564
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32189430
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-839729
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6885061
us-gaap Net Income Loss
NetIncomeLoss
-7159464
us-gaap Net Income Loss
NetIncomeLoss
-15316292
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1047749
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
811763
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1043280
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
868243
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1887478
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6073298
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8202744
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14448049
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
24322490
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1088173
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
56201375
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1047749
CY2020Q3 ctso Stock Issued During Period Value Stock Cash Options Exercised
StockIssuedDuringPeriodValueStockCashOptionsExercised
179752
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
328841
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-839729
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
80233153
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3418042
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2863805
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
80214008
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1043280
ctso Stock Issued During Period Value Stock Cash Options Exercised
StockIssuedDuringPeriodValueStockCashOptionsExercised
1282262
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
657780
us-gaap Net Income Loss
NetIncomeLoss
-7159464
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
80233153
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
11542661
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
802334
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
811763
CY2019Q3 ctso Stock Issued During Period Value Stock Cash Options Exercised
StockIssuedDuringPeriodValueStockCashOptionsExercised
312246
CY2019Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
237729
CY2019Q3 ctso Adjustments To Additional Paid In Capital Fees Related To Open Market Sales Agreement
AdjustmentsToAdditionalPaidInCapitalFeesRelatedToOpenMarketSalesAgreement
-87881
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6885061
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
6733791
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
16934600
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1174755
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
868243
ctso Stock Issued During Period Value Stock Cash Options Exercised
StockIssuedDuringPeriodValueStockCashOptionsExercised
728507
us-gaap Net Income Loss
NetIncomeLoss
-15316292
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
994981
us-gaap Depreciation And Amortization
DepreciationAndAmortization
414115
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
107604
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1006960
us-gaap Depreciation And Amortization
DepreciationAndAmortization
494996
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
79338
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-77636
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-44186
us-gaap Share Based Compensation
ShareBasedCompensation
2863805
us-gaap Share Based Compensation
ShareBasedCompensation
1174755
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1416577
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-1051854
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1083938
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-408783
ctso Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
0
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
663368
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
ctso Adjustments To Additional Paid In Capital Fees Related To Open Market Sales Agreement
AdjustmentsToAdditionalPaidInCapitalFeesRelatedToOpenMarketSalesAgreement
-87881
ctso Stock Issued During Period Value Stock Cash Warrants Exercised
StockIssuedDuringPeriodValueStockCashWarrantsExercised
1768491
us-gaap Net Income Loss
NetIncomeLoss
-15316292
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
6733791
us-gaap Net Income Loss
NetIncomeLoss
-7159464
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-128727
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
964478
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1104461
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
43645
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-4047
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-512439
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-405820
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4555480
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12634569
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
546389
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
557411
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
863693
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
559483
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1410082
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1116894
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
80214008
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
87881
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1410900
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
5000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1410900
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
ctso Payments Of Debt Issuance Cost
PaymentsOfDebtIssuanceCost
0
ctso Payments Of Debt Issuance Cost
PaymentsOfDebtIssuanceCost
4212
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1282262
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
728507
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1768491
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
81496270
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7404905
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
215217
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-44336
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
75745925
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6390894
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12232418
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22368837
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87978343
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15977943
us-gaap Interest Paid Net
InterestPaidNet
883857
us-gaap Interest Paid Net
InterestPaidNet
732537
us-gaap Stock Issued1
StockIssued1
657780
us-gaap Stock Issued1
StockIssued1
425639
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">1.    BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The interim consolidated financial statements of CytoSorbents Corporation (the “Company”) have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments, for a fair statement of the Company’s consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on March 5, 2020. The results for the three and nine months ended September 30, 2020 and 2019 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to June 30, 2020, the Company's consolidated financial statements were prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July 24, 2020, the Company closed an underwritten public offering of 6,052,631 shares of its common stock at a public offering price of $9.50 per share (the “Offering”).  Gross proceeds from the Offering amounted to approximately $57.5 million and, after deducting the underwriting discounts and commissions and expenses related to the Offering, the Company received total net proceeds of approximately $53.8 million. See Note 3. As of September 30, 2020, the Company’s cash balance was approximately $88.0 million, which the Company expects will fund the Company’s operations well beyond the next twelve months. As a result, the Company has determined that the going concern risk has been eliminated.</p>
CY2020Q3 us-gaap Cash
Cash
88000000.0
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1381000
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-956000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1417000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1052000
CY2020Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
637735
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
305452
CY2020Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1137834
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1523923
CY2020Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
249365
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
284522
CY2020Q3 us-gaap Advertising Expense
AdvertisingExpense
32000
CY2019Q3 us-gaap Advertising Expense
AdvertisingExpense
70000
us-gaap Advertising Expense
AdvertisingExpense
118000
us-gaap Advertising Expense
AdvertisingExpense
215000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. The valuation of options granted is a significant estimate in these consolidated financial statements.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A significant portion of our revenues are from product sales in Germany. Substantially all of our grant and other income are from grant agencies in the United States. (See Note 4 for further information relating to the Company’s revenue.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, one distributor accounted for approximately 20% of outstanding grants and accounts receivable.  As of December 31, 2019, no agency, distributor/strategic partners or direct customer represented more than 10% of outstanding grants and accounts receivables. For the three months ended September 30, 2020, one distributor accounted for approximately 13% of the Company's total revenue. For the nine months ended September 30, 2020, no agency, distributor, or direct customer represented more than 10% of the Company’s total revenue. For the three and nine months ended September 30, 2019, no agency, distributor, or direct customer represented more than 10%of the Company’s total revenue. </p>
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q3 ctso Aggregate Registered Amount For Offerings
AggregateRegisteredAmountForOfferings
150000000
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4301869
CY2020Q3 us-gaap Share Price
SharePrice
6.53
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27238000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
49000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1088000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
802000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2864000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1175000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4218189
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.16
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1593825
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.18
ctso Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
P9Y3M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
31644
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
224047
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.60
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
321375
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.35
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5234948
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.36
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0028
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0036
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
7.975
CY2020Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3180106
CY2020Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
6.15
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6104740
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1183790
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1593825
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.74
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
31641
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
3.75
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
691135
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.26
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2054842
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.00
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3233000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P30M
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1041325
CY2020Q1 ctso Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Tranches
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingTranches
4
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6279000
ctso Share Based Compensation Option Milestones Met By The Company Percentage
ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage
0.625
CY2020Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
419000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
616000
CY2019Q4 us-gaap Deferred Revenue
DeferredRevenue
171842
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10546612
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6095007
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
29048825
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
17519162
ctso Number Of Primary Revenue Streams
NumberOfPrimaryRevenueStreams
2
CY2020Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
3175385
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2246821
CY2020Q3 us-gaap Deferred Revenue
DeferredRevenue
163241
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
ctso Debt Instrument Non Refundable Fee Upon Termination Or Maturity Percent
DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent
0.025
CY2020Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15000000
CY2020Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
51145
CY2020Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
210937
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
15159792
CY2020Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
9166667
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5993125
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
9166667
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
5833333
CY2020Q3 ctso Long Term Debt And Final Fee
LongTermDebtAndFinalFee
15000000
CY2020Q2 ctso Loan Proceeds From Payroll Protection Program
LoanProceedsFromPayrollProtectionProgram
1411000
ctso Executive Employment Agreements Initial Term
ExecutiveEmploymentAgreementsInitialTerm
P3Y
ctso License Period
LicensePeriod
P18Y
CY2018Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0916
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1131915
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1070762
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1131915
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1070762
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
432423
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
428083
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
699492
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
642679
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
432423
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
345067
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
78823
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
86354
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
94605
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due After Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
94643
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1131915
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
211000
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
234000
us-gaap Operating Lease Payments
OperatingLeasePayments
658000
us-gaap Operating Lease Payments
OperatingLeasePayments
674000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D

Files In Submission

Name View Source Status
0001104659-20-121349-index-headers.html Edgar Link pending
0001104659-20-121349-index.html Edgar Link pending
0001104659-20-121349.txt Edgar Link pending
0001104659-20-121349-xbrl.zip Edgar Link pending
ctso-20200930.xsd Edgar Link pending
ctso-20200930x10q.htm Edgar Link pending
ctso-20200930x10q_htm.xml Edgar Link completed
ctso-20200930xex31d1.htm Edgar Link pending
ctso-20200930xex31d2.htm Edgar Link pending
ctso-20200930xex32d1.htm Edgar Link pending
ctso-20200930xex32d2.htm Edgar Link pending
ctso-20200930_cal.xml Edgar Link unprocessable
ctso-20200930_def.xml Edgar Link unprocessable
ctso-20200930_lab.xml Edgar Link unprocessable
ctso-20200930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending